Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1002 PK/PD in Renal Impairment
NCT05323136Phase 1Terminated
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Apr 2022
- Primary completion
- Jun 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MT1002 in acute coronary syndrome (ACS) (2 arms), sponsored by Shaanxi Micot Technology Co., Ltd. Primary endpoints: Plasma Pharmacokinetics at 24 hour and Urine Pharmacokinetics at 24 hour. Started Apr 2022; status: terminated.
02
Drugs
MT1002
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT05323136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323136.